Cargando…
How Full-Length FVIII Benefits from Its Heterogeneity – Insights into the Role of the B-Domain
PURPOSE: To explore how the natural heterogeneity of human coagulation factor VIII (FVIII) and the processing of its B-domain specifically modulate protein aggregation. METHODS: Recombinant FVIII (rFVIII) molecular species containing 70% or 20% B-domain, and B-domain-deleted rFVIII (BDD-rFVIII), wer...
Autores principales: | Anzengruber, Julia, Feichtinger, Martin, Bärnthaler, Philipp, Haider, Norbert, Ilas, Josenato, Pruckner, Nina, Benamara, Karima, Scheiflinger, Friedrich, Reipert, Birgit M., Malisauskas, Mantas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443606/ https://www.ncbi.nlm.nih.gov/pubmed/30937539 http://dx.doi.org/10.1007/s11095-019-2599-2 |
Ejemplares similares
-
Comparative analysis of marketed factor VIII products: reply
por: Reipert, B. M., et al.
Publicado: (2018) -
Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells
por: Lubich, Christian, et al.
Publicado: (2022) -
Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022) -
Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1(+) Tregs
por: Becker-Gotot, Janine, et al.
Publicado: (2022) -
Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
por: Paul, Helmut, et al.
Publicado: (2022)